The 4 biggest pharma market access stories of 2019

What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive into the pharmaphorum archives to find out.

Sumitomo and Roivant put flesh on bones of $3bn R&D deal

After four-year wait, patients in England finally get Vertex...

NHS England has signed an agreement with US pharma Vertex covering all the company’s licensed cystic fibrosis medicines, and any future uses for them.

Vertex gets early okay for cystic fibrosis triple Trikafta i...

UK’s Enterprise gets £5.7m backing for ‘universal’ cystic fi...

Labour government would use compulsory licensing for expensi...